Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party-Reference-Cited by-同舟云学术

Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party

Published:2016-04-27 Issue:10 Volume:30 Page:2047-2054
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Sobh M,Michallet M,Gahrton G,Iacobelli S,van Biezen A,Schönland S,Petersen E,Schaap N,Bonifazi F,Volin L,Meijer E,Niederwieser D,El-Cheikh J,Tabrizi R,Fegeux N,Finke J,Bunjes D,Cornelissen J,Einsele H,Bruno B,Potter M,Fanin R,Mohty M,Garderet L,Kröger N

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2016101.pdf

Reference53 articles.

1. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516–2520.

2. Palumbo A, Anderson K . Multiple myeloma. N Engl J Med 2011; 364: 1046–1060.

3. Cavo M, Pantani L, Pezzi A, Petrucci MT, Patriarca F, Di Raimondo F et al. Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma. Leukemia 2015; 29: 2429–2431.

4. Garderet L, Iacobelli S, Moreau P, Dib M, Lafon I, Niederwieser D et al. Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2012; 30: 2475–2482.

5. Harousseau JL, Attal M, Avet-Loiseau H, Marit G, Caillot D, Mohty M et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol 2010; 28: 4621–4629.

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and survival outcome of allogeneic stem-cell transplantation in multiple myeloma: meta-analysis in the recent 10 years;Frontiers in Oncology;2024-07-31

2. Allogeneic stem cell transplantation in multiple myeloma: is there still a place?;Frontiers in Oncology;2024-06-04

3. Positron Emission Tomography/Computed Tomography Transformation of Oncology;PET Clinics;2024-04

4. Hematopoietic Cell Transplantation in Multiple Myeloma;Manual of Hematopoietic Cell Transplantation and Cellular Therapies;2024

5. Allogeneic Hematopoietic Stem Cell Transplant;Comprehensive Hematology and Stem Cell Research;2024